Apex Research Foundation LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$89,460	8
2024	Research	$82,528	4
2023	Research	$137,401	5
2022	Research	$38,216	4
2021	Research	$36,697	14
2020	Research	$35,808	9

Breakdown

Who paid Research payments · program years 2020–2025

Novartis Pharmaceuticals Corporation $374,856 18 payments
Eli Lilly and Company $18,666 2 payments
Bayer HealthCare Pharmaceuticals Inc. $15,948 9 payments
Vifor (International) Ltd. $5,852 6 payments
Esperion Therapeutics, Inc. $4,788 9 payments

Studies the money was for Research payments · program years 2020–2025

Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $142,277 3 payments
A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $98,780 4 payments
Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease $47,104 2 payments
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $22,794 1 payment
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease $22,364 1 payment
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $22,235 3 payments
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) $15,948 9 payments
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) $13,662 1 payment
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $9,436 1 payment
A Randomized Double-Blind Placebo-Controlled Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $9,230 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.